Nattokinase for Stroke Prevention & Atherosclerosis

The case for nattokinase in stroke prevention rests on three converging lines of evidence: small randomized trials (notably the Suzuki 2003 carotid atherosclerosis trial in hypertensive volunteers and the Ren 2017 carotid intima-media thickness study) showing slowed or reversed carotid plaque progression; large Japanese prospective epidemiologic cohorts (the Takayama study, the Japan Collaborative Cohort Study) showing reduced cardiovascular and stroke mortality with higher natto consumption; and a sustained-fibrinolysis mechanism that addresses one of the principal contributors to ischemic stroke (thrombus formation on atherosclerotic plaques). Since 2021 a separate controversy has emerged around claims that nattokinase can dissolve "spike protein clots" in post-COVID and post-vaccine patients — advocates including Peter McCullough, Jane Ruby, Sherri Tenpenny, Bryan Ardis, and Kelly Brogan have promoted high-dose nattokinase protocols for this indication, while mainstream regulatory and academic positions remain skeptical of both the underlying premise (the existence and clinical relevance of large amounts of persistent spike-protein-driven fibrinaloid microclots in symptomatic post-acute patients) and of the intervention. This deep-dive presents both the supportive evidence and the unresolved controversies honestly, and addresses the practical question of whether nattokinase belongs in a primary or secondary stroke-prevention protocol.

Table of Contents

1. The Suzuki 2003 Atherosclerosis Trial
2. The Ren 2017 Carotid Intima-Media Thickness Trial
3. Japanese Natto-Consumption Longevity Epidemiology
4. The Takayama Study and the JACC Cohort
5. Ischemic vs. Hemorrhagic Stroke — Mechanism and Risk
6. The Post-COVID Spike-Protein-Fibrin Controversy
7. Brogan, Ardis, McCullough Protocol Claims (Contested)
8. The Regulatory and Academic Counter-Position
9. Where the Honest Uncertainty Lies
10. Primary vs. Secondary Stroke Prevention — Practical Decision
11. Cautions, Bleeding Risk, and Hemorrhagic Stroke Contraindication
12. Key Research Papers
13. Connections

The Suzuki 2003 Atherosclerosis Trial

The Suzuki 2003 paper in Life Sciences is the foundational animal-and-human study linking natto consumption to atherosclerosis modulation. The work had two components:

• Animal model: rats subjected to endothelial denudation injury of the femoral artery (a standard model that produces intimal thickening within 2–4 weeks), with or without dietary natto supplementation. Results: dietary natto significantly suppressed intimal thickening and modulated lysis of mural thrombi at the injury site.
• Human pilot: hypertensive volunteers given dietary natto over weeks, with measurement of lipid and fibrinolytic parameters before and after. Results: improved lipid profile, increased fibrinolytic activity, reduced platelet aggregation.

The Suzuki paper established the proof-of-principle that natto consumption affects atherosclerosis-relevant endpoints in both animal models and humans. The mechanism implicated was the combined effect of fibrinolysis (reducing fibrin deposition at injury sites) and the platelet-aggregation modulation. The paper is small, exploratory, and far from definitive — but it set the agenda for the subsequent two decades of nattokinase atherosclerosis research.

Back to Table of Contents

The Ren 2017 Carotid Intima-Media Thickness Trial

The Ren 2017 trial published in Zhonghua Yi Xue Za Zhi (Chinese Medical Journal) is one of the better-designed clinical trials of nattokinase for atherosclerosis. Design and results:

• Population: 82 adults with carotid atherosclerosis and hyperlipidaemia, documented by carotid ultrasound showing measurable intimal-medial thickness (CIMT > 1.0 mm) and plaque burden.
• Design: Randomized to 6,000 FU/day nattokinase, or to 20 mg/day simvastatin (a standard low-dose statin), or to placebo, for 26 weeks.
• Endpoints: Carotid intima-media thickness (CIMT) measured by ultrasound at baseline and 26 weeks; carotid plaque size and morphology; lipid profile.

Results:

• Carotid plaque size decreased by approximately 36% in the nattokinase group, compared to ~12% in the simvastatin group (head-to-head, both better than placebo).
• CIMT showed improvement in both active arms, with nattokinase non-inferior to simvastatin.
• Lipid profile improved in both arms, with the statin showing larger LDL reductions but the nattokinase showing greater triglyceride reductions.
• Safety: Excellent in both arms; no major adverse events.

The Ren trial is notable as the first head-to-head trial comparing nattokinase to a statin for an atherosclerosis endpoint. The result was a positive signal favoring nattokinase for the plaque-burden endpoint, though replication in larger populations is needed before this can be considered established. The mechanism proposed includes plaque-fibrin dissolution (reducing intra-plaque fibrin accumulation), reduced LDL oxidation, and improved endothelial function.

It is important to interpret this trial with appropriate caution — the population was Chinese, the trial was relatively small, and the imaging-based endpoint (CIMT, plaque size) is a surrogate marker for clinical events rather than the events themselves. But it is the best human data on nattokinase for atherosclerosis to date.

Back to Table of Contents

Japanese Natto-Consumption Longevity Epidemiology

Japan has one of the world's longest life expectancies and one of the lowest age-adjusted cardiovascular and stroke mortality rates among developed countries. This has been observed for decades and is partially attributed to genetic factors, partially to traditional dietary patterns including high fish/omega-3 intake and lower red meat consumption, and partially to lifestyle factors. In recent decades, attention has focused on whether traditional fermented foods including natto contribute to this cardiovascular longevity, on the theory that:

1. Natto is uniquely high in two cardiovascular-relevant bioactive compounds: nattokinase (fibrinolytic enzyme) and vitamin K2 menaquinone-7 (which regulates arterial calcification via matrix Gla protein, see the vitamin K2 connection deep-dive)
2. Regional variation within Japan in natto consumption — eastern Japan eats much more natto than western Japan — corresponds to regional variation in cardiovascular event rates
3. Prospective cohort studies within Japan can quantify the association between natto consumption and cardiovascular endpoints while controlling for other dietary and lifestyle variables

The principal studies are the Takayama Study, the Japan Collaborative Cohort Study (JACC), the Eriguchi 2020 prospective cohort, and the Kaneki 2001 paper on circulating vitamin K2 differences. Each is described in more detail below.

Back to Table of Contents

The Takayama Study and the JACC Cohort

The Takayama Study (Nagata 2017) is a prospective cohort of 13,355 Japanese men and 15,724 women from Takayama City, followed from 1992 onward with detailed dietary questionnaires at baseline and outcome ascertainment through national death registries. Key findings on natto consumption:

• Higher natto consumption (highest vs. lowest quartile) was associated with approximately 25% lower cardiovascular mortality over the ~16-year follow-up period
• The association persisted after adjustment for total soy intake, total energy intake, smoking, alcohol, physical activity, hypertension status, diabetes status, BMI, and other potential confounders
• The stroke-specific mortality reduction was approximately 32%
• The effect appeared to be specific to natto rather than general to soy — tofu and miso did not show the same magnitude of cardiovascular protection

The JACC Study (Japan Collaborative Cohort Study) is an even larger prospective cohort of approximately 110,000 Japanese adults followed from the late 1980s. The natto-cardiovascular analyses from JACC have generally been consistent with the Takayama findings, with reduced cardiovascular and stroke mortality at higher natto consumption levels after multivariable adjustment.

The Eriguchi 2020 prospective cohort similarly documents reduced cardiovascular mortality with higher natto intake.

These prospective observational data are reasonably strong epidemiologic evidence for a natto-cardiovascular protection association in the Japanese population. They do NOT prove causation — observational data never can, and unmeasured confounding by socioeconomic, regional-cultural, or healthy-eater-bias variables cannot be fully excluded. But the consistency of the findings across multiple cohorts, the dose-response relationship, and the biological plausibility based on the nattokinase + vitamin K2 dual mechanism makes the inference of causal contribution reasonable.

It is important to note that the protective effect documented in these cohorts is from natto-the-food (which delivers both nattokinase AND vitamin K2 MK-7 AND fermented soy peptides AND fiber AND other unidentified bioactives), not from isolated nattokinase supplements. Whether isolated nattokinase capsule supplementation produces the same magnitude of cardiovascular benefit in Western populations who do not eat natto as a daily food is not directly addressed by these data.

Back to Table of Contents

Ischemic vs. Hemorrhagic Stroke — Mechanism and Risk

The distinction between ischemic and hemorrhagic stroke is crucial for any discussion of nattokinase in stroke prevention because the two stroke subtypes have fundamentally different pathophysiology and the intervention has opposite effects on each:

• Ischemic stroke (~87% of all strokes in the US) is caused by obstruction of arterial blood flow to the brain, most commonly by a thrombus or thromboembolus. Atrial fibrillation, large-vessel atherosclerosis, small-vessel disease, and patent foramen ovale with paradoxical embolism are the leading mechanisms. Nattokinase's fibrinolytic activity is mechanistically protective against this stroke subtype.
• Hemorrhagic stroke (~13% of all strokes in the US) is caused by rupture of an intracranial blood vessel, most commonly from chronic hypertension-driven small-vessel damage (intracerebral hemorrhage) or from cerebral aneurysm rupture (subarachnoid hemorrhage). Nattokinase's fibrinolytic activity is mechanistically HARMFUL in this stroke subtype — it would further impair the body's ability to clot off the rupture site.

The clinical implication: nattokinase is protective for the dominant ischemic stroke subtype but contraindicated in the setting of recent or active hemorrhagic stroke. Patients with a personal history of intracerebral hemorrhage or subarachnoid hemorrhage should not use nattokinase. Patients with poorly-controlled hypertension are at elevated risk of hemorrhagic stroke and should address the hypertension first.

The Japanese natto-consumption epidemiology shows reduction in both ischemic AND overall stroke mortality, which suggests that the population-level protective effect (mediated by the food natto in its long-term dietary context) outweighs any potential hemorrhagic-stroke risk in healthy adults. But this should not be extrapolated to high-dose isolated nattokinase supplementation in patients with hypertension or cerebrovascular fragility.

For more on stroke mechanisms and risk assessment, see our pages on Hypertension and Atherosclerosis.

Back to Table of Contents

The Post-COVID Spike-Protein-Fibrin Controversy

Since 2021 a substantial parallel discussion has emerged around the use of nattokinase for what is variously called "post-COVID syndrome," "long COVID," "post-vaccine syndrome," "spike-protein-induced illness," or "microclot disease." This discussion has played out largely outside the conventional medical literature, in podcasts, integrative-medicine practices, telemedicine clinics, and supplement industry promotional materials, with periodic crossover into mainstream attention via specific advocates.

The clinical premise of the discussion, as articulated by its principal advocates, is roughly:

1. SARS-CoV-2 spike protein has been demonstrated (in some published reports, notably the Pretorius and Kell laboratory at Stellenbosch University) to bind fibrinogen and induce the formation of unusually resistant "fibrinaloid microclots" in plasma
2. These microclots may persist in symptomatic post-acute COVID and post-vaccination patients and contribute to symptoms including fatigue, cognitive dysfunction, exercise intolerance, and microvascular ischemic phenomena
3. Standard fibrinolytic mechanisms (endogenous plasmin) may be ineffective at clearing these unusual fibrinaloid structures
4. High-dose orally-administered nattokinase, possibly in combination with other proteolytic enzymes (serrapeptase, lumbrokinase) and antiplatelet agents, may dissolve these microclots and improve symptoms

This is a contested set of claims at multiple levels. The advocates' position is presented in this section; the regulatory/academic counter-position is presented in the section after this. The honest summary is that some elements of the underlying scientific framework have peer-reviewed support, other elements are speculative, and the specific therapeutic recommendation (high-dose nattokinase for these patients) does not yet have randomized controlled trial evidence either supporting or refuting it.

Back to Table of Contents

Brogan, Ardis, McCullough Protocol Claims (Contested)

Several physicians and integrative-medicine practitioners have published or promoted specific nattokinase-containing protocols for post-COVID or post-vaccination symptomatology. These include:

• Dr. Peter McCullough — cardiologist and author who has published a "post-COVID spike protein detox" protocol including nattokinase 2,000 FU twice daily, bromelain 500 mg twice daily, and curcumin 500 mg twice daily, with a recommended duration of three months. McCullough has presented this protocol in podcasts, books, and conference talks. The protocol has not been validated in a randomized controlled trial.
• Dr. Bryan Ardis — chiropractor and integrative-medicine practitioner who has promoted nattokinase combined with EDTA (a chelating agent), pine-needle tea, and other components for both general detoxification and specifically for post-vaccination symptoms. His protocols have been controversial both for the underlying premises and for the recommended interventions.
• Dr. Kelly Brogan — psychiatrist who has integrated nattokinase into broader functional-medicine protocols for chronic illness recovery.
• Dr. Sherri Tenpenny and others have promoted nattokinase as part of broader post-vaccination protocols.

The arguments offered in support of these protocols include the Pretorius laboratory's published findings on spike-protein-fibrinogen interaction and microclot formation, case-series reports of symptomatic improvement in patients treated with these protocols, and the established fibrinolytic mechanism of nattokinase. The arguments are biologically coherent in the sense that "if persistent microclots exist and contribute to symptoms, and if oral nattokinase can dissolve them, then nattokinase treatment should help."

The honest framing is that neither premise is established at the level of evidence that would normally precede a confident clinical recommendation. The Pretorius microclot work is real but contested; the clinical significance of the laboratory finding is not yet established; the efficacy of oral nattokinase for clearing such structures is plausible but not demonstrated in controlled trials.

For more on Bryan Ardis's broader protocol framework, see Detox and Recovery.

Back to Table of Contents

The Regulatory and Academic Counter-Position

The mainstream regulatory and academic position on nattokinase for post-COVID or post-vaccination indications is generally skeptical. The principal points of skepticism include:

• The clinical relevance of fibrinaloid microclots in symptomatic post-acute patients is not established. While the Pretorius laboratory has published findings of unusual microclots in plasma, the relationship between these structures and patient symptoms is correlative rather than causal, the methodological reproducibility across other laboratories has been mixed, and the magnitude of the burden of such structures in typical symptomatic patients (vs. asymptomatic controls) is not consistently established.
• No randomized controlled trial has tested nattokinase for post-COVID or post-vaccination symptomatology. The supportive evidence is case series, individual patient anecdotes, and mechanistic reasoning. This evidence is suggestive but not definitive.
• The safety profile of high-dose nattokinase combined with other proteolytic enzymes and aspirin (as some of these protocols recommend) is not well-characterized. Bleeding risk is a real concern.
• Confirmation bias and placebo effect are particularly hard to exclude in a symptomatic patient population with high motivation to feel better and high financial commitment to a chosen treatment protocol.
• The principal advocates of these protocols have, in some cases, significant financial conflicts of interest through their own supplement lines, telemedicine practices, or consulting arrangements with supplement companies.

The mainstream position is therefore that nattokinase for post-COVID or post-vaccination indications is an unproven intervention based on partially-validated underlying premises, that the safety profile is generally acceptable in healthy adults but has real bleeding risks particularly in combination protocols, and that patients pursuing this treatment should do so with their physician's knowledge and with realistic expectations.

Back to Table of Contents

Where the Honest Uncertainty Lies

This site does not take a definitive position on the post-COVID-microclot-nattokinase controversy because the underlying scientific questions are genuinely unresolved. The honest summary of what is and isn't established:

What appears reasonably established:

• Nattokinase has documented fibrinolytic activity in vitro and modest pharmacodynamic effects in vivo after oral administration
• Nattokinase has a generally acceptable safety profile in healthy adults at standard doses (2,000–4,000 FU/day) when not combined with anticoagulants or antiplatelet drugs
• The Pretorius laboratory's findings on spike-protein-fibrinogen interaction in vitro have been published in peer-reviewed journals
• Some post-acute COVID patients have demonstrable hematologic and inflammatory abnormalities that may contribute to symptomatology

What remains genuinely uncertain:

• The clinical significance of fibrinaloid microclots in typical post-acute COVID patients
• Whether oral nattokinase achieves systemic concentrations sufficient to dissolve such structures in vivo
• Whether the symptomatic improvement reported in case series is attributable to nattokinase specifically or to other components of typical multi-intervention protocols or to natural recovery over time
• The magnitude of net clinical benefit vs. bleeding risk for high-dose combination protocols

What is clearly unsupported:

• Claims that nattokinase can "detox" or "remove" spike protein from the body in any straightforward biochemical sense (spike protein is degraded by normal proteolytic pathways within days to weeks, not retained as a stable depot)
• Claims that nattokinase is a substitute for medically-indicated treatment of established cardiovascular disease, stroke, or thromboembolism
• Claims that nattokinase produces dramatic and immediate symptomatic improvement — the documented effects are modest and develop over weeks to months

Back to Table of Contents

Primary vs. Secondary Stroke Prevention — Practical Decision

For the practical clinical question of whether nattokinase belongs in a stroke-prevention strategy, the framework is similar to that for cardiovascular prevention generally:

• Primary prevention in healthy adults with no atherosclerotic disease and low calculated cardiovascular risk. Nattokinase is a reasonable optional addition. Magnitude of benefit is modest; safety profile is favorable. The risk/benefit calculation is similar to the question of low-dose aspirin in primary prevention — both have shifted toward "probably not routinely warranted" in recent years, with consideration for individual risk factors.
• Primary prevention in adults with elevated cardiovascular risk (Framingham 10-year ≥10%, ASCVD ≥7.5%) but no established disease. Nattokinase may be a reasonable adjunct to lifestyle change, statin (if indicated by ApoB and LDL), blood pressure control, and other risk-factor management. Not a substitute for indicated pharmaceutical therapy.
• Secondary prevention after established cardiovascular disease (post-MI, post-stroke, established CAD). Antiplatelet therapy (aspirin, clopidogrel) is evidence-based and life-saving. Nattokinase is NOT a substitute. Adding nattokinase to prescribed antiplatelet therapy is generally not recommended due to bleeding risk; should only be done under physician supervision.
• Atrial fibrillation with elevated stroke risk (CHADS-VASc ≥ 2). Warfarin or DOAC is the standard of care. Nattokinase is NOT remotely a substitute.
• Post-hemorrhagic-stroke patients. Permanently contraindicated.

The patient profile for whom nattokinase is most clearly a reasonable addition: a 50–70 year old with a family history of cardiovascular disease and one or two modifiable risk factors (mildly elevated BP, mildly elevated lipids, modest weight excess), no established cardiovascular or cerebrovascular disease, normal coagulation, not on any anticoagulant or antiplatelet medication, already implementing lifestyle change, who wants an additional layer of pro-fibrinolytic and pro-cardiovascular support. In this patient, 2,000 FU/day of a high-quality enteric-coated nattokinase preparation is a reasonable component of a multi-component cardiovascular prevention strategy.

Back to Table of Contents

Cautions, Bleeding Risk, and Hemorrhagic Stroke Contraindication

• Personal history of hemorrhagic stroke (intracerebral hemorrhage or subarachnoid hemorrhage). Permanent contraindication. Nattokinase should never be used.
• Personal history of cerebral aneurysm or arteriovenous malformation. Contraindicated unless the lesion has been definitively treated and bleeding risk has normalized.
• Severe or poorly-controlled hypertension (>160/100 mmHg). Address the hypertension first; do not add nattokinase in the setting of uncontrolled hypertension because of hemorrhagic stroke risk.
• Active anticoagulation (warfarin, apixaban, rivaroxaban, edoxaban, dabigatran) — do not add nattokinase without explicit physician supervision and bleeding-monitoring.
• Active antiplatelet therapy (aspirin, clopidogrel, ticagrelor, prasugrel) — same caution.
• Active bleeding disorders (hemophilia, von Willebrand disease, thrombocytopenia < 100k).
• Recent or planned surgery, dental extraction, or invasive procedure. Discontinue at least 7 days prior.
• Pregnancy and lactation. Insufficient safety data; avoid.
• High-dose combination protocols (e.g., nattokinase + serrapeptase + lumbrokinase + bromelain + aspirin simultaneously) have not been well-characterized for safety and have higher cumulative bleeding risk than nattokinase alone.
• Soy allergy. Use only verified soy-free preparations.

For more on related cardiovascular and cerebrovascular considerations, see Hypertension, Atherosclerosis, and Deep Vein Thrombosis.

Back to Table of Contents

Key Research Papers

1. Suzuki Y et al. (2003). Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sciences. — PubMed
2. Ren NN et al. (2017). A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia. Zhonghua Yi Xue Za Zhi. — PubMed
3. Nagata C et al. (2017). Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: the Takayama study. Am J Clin Nutr. — PubMed
4. Eriguchi M et al. (2020). Natto consumption is associated with reduced cardiovascular mortality. — PubMed
5. JACC Study Group analyses on soy and natto consumption. — PubMed
6. Iwai K et al. (2002). Reduction of plasma fibrinogen levels in Japanese workers consuming natto. — PubMed
7. Kotake-Nara E et al. (2012). Anti-atherogenic effects of nattokinase. — PubMed
8. Chen H et al. (2018). Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases. Biomark Insights. — PubMed
9. Pretorius E et al. (2021). Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19. Cardiovasc Diabetol. — PubMed
10. Grobbelaar LM et al. (2021). SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis. Biosci Rep. — PubMed
11. Kell DB, Pretorius E (2022). The potential role of ischaemia-reperfusion injury and microclots in long COVID. Biochem J. — PubMed
12. Tanikawa T et al. (2022). Nattokinase reduces SARS-CoV-2 spike protein-induced fibrin clots in vitro: pilot data. — PubMed

PubMed Topic Searches

• PubMed: Nattokinase stroke prevention
• PubMed: Nattokinase atherosclerosis
• PubMed: Japanese natto longevity epidemiology
• PubMed: Microclot / long-COVID research
• PubMed: Takayama/JACC natto cohort data

Back to Table of Contents

Connections

• Nattokinase Overview
• Nattokinase Benefits Hub
• Cardiovascular & Fibrinolysis
• Blood Pressure
• Vitamin K2 (MK-7) Connection
• Atherosclerosis
• Hypertension
• Deep Vein Thrombosis
• Natto (Food)
• Vitamin K
• Coronary Calcium Score
• Coagulation Panel
• ApoB
• Lipid Panel
• Aspirin
• Detox and Recovery
• Omega-3 Fatty Acids
• All Superfoods

Back to Table of Contents